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Possible anthrax exposure in Department of Defense Mail Facility
Samples taken from a mail facility at the Pentagon at a Remote Delivery Facility (RDF) on March 
10 tested positive for Bacillus anthracis. The Department of Defense (DOD) briefed all personnel 
who may have had contact with the mail at the Pentagon RDF. These employees are being 
provided with antibiotics as a prophylactic measure. Based on the route of mail reaching the 
Pentagon, CDC has made the following public health recommendations for U SPS  postal workers 
at the V Street Postal Facility in Washington DC where the DOD mail was processed prior to 
being sent to the
Pentagon
1) Active medical follow-up should be initiated; that is, interviews with possibly affected workers 
for evidence of symptoms and review of sick leave records.
2) Although risk is considered low, based on an abundance of caution a course of prophylactic 
antibiotics (doxycycline or ciprofloxacin; both are equally effective) is recommended until tests 
determining possible exposure to B. anthracis at the V Street facility can be conducted.
CDC has also recommended DOD follow up immediately with other non-USPS commercial mail 
carriers that deliver to the DOD facility to share the information on:
1) Positive alarm signals
2) Recommendations for U SPS  workers, so that those carriers can take steps as needed to 
follow up with their employees.
Extensive environmental sampling will be conducted in the Pentagon’s RDF and the V Street
Postal Facility to determine the extent of anthrax contamination.
Clinicians and public health agencies are encouraged to heighten their surveillance for typical 
symptoms and exposure history for B. anthracis. Clinicians should report suspected or confirmed 
anthrax cases immediately to your local or state department of health.
Anthrax causes and transmission
Anthrax is caused by exposure to B. anthracis an encapsulated, aerobic, gram-positive, spore- 
forming, rod-shaped bacterium. Depending on the route of infection, human anthrax can occur in 
three clinical forms: cutaneous, inhalational, and gastrointestinal. Direct skin contact with 
contaminated animal products can result in cutaneous anthrax. Inhalation of aerosolized spores, 
such as through industrial processing of contaminated wool, hair, or hides, can result in 
inhalational anthrax. Hemorrhagic meningitis can result from hematogenous spread of the 
organism following any form of the disease.
The incubation period for anthrax is generally <2 weeks. However, due to spore dormancy and 
slow clearance from the lungs, the incubation period for inhalational anthrax may be
prolonged. This phenomenon of delayed onset of disease is not recognized to occur with 
cutaneous or gastrointestinal exposures.
Skin/cutaneous anthrax
Skin or cutaneous anthrax is the most common type of naturally-acquired infection. Infection 
begins as a pruritic papule or vesicle that enlarges and erodes (1-2 days) leaving a necrotic ulcer 
with subsequent formation of a central black eschar (Images at
http://www.bt.cdc.gov/Agent/cutaneous.asp]). The lesion is usually painless with surrounding 
edema, hyperemia, and regional lymphadenopathy. Patients may have associated fever, malaise 
and headache. Historically, the case-fatality rate for cutaneous anthrax has been <1% with 
antibiotic treatment and 20% without antibiotic treatment. There are rare case reports of person- 
to-person transmission of cutaneous disease.
See http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm#tab2 for specific treatment of 
cutaneous anthrax.
Inhalational anthrax
Inhalational anthrax is rare but is the most lethal form of the disease. Disease may initially involve 
a prodrome of fever, chills, nonproductive cough, chest pain, headache, myalgias, and malaise.
However, more distinctive clinical hallmarks include hemorrhagic mediastinal lymphadenitis, 
hemorrhagic pleural effusions, bacteremia and toxemia resulting in severe dyspnea, hypoxia and 
septic shock. Widened mediastinum is the classic finding on imaging of the chest, but may initially 
be subtle (Images at http://www.bt.cdc.gov/Agent/inhalational.asp and in the appendices). Case- 
fatality rates for inhalational anthrax are high, even with appropriate antibiotics, and supportive 
care. Following the bioterrorist attack in fall 2001, the case-fatality rate among patients with 
inhalational disease was 45% (5/11). Person-to person spread of inhalational anthrax has not 
been documented.
For case definitions, treatment guidelines, laboratory testing procedures, etc, see Anthrax 
Information for Health Care Providers
http://www.bt.cdc.gov/agent/anthrax/anthrax-hcp-factsheet.asp
For information on mail handler protection related to anthrax, see 
http://www.bt.cdc.gov/agent/anthrax/mail/index.asp
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